Allergy Therapeutics launches biomarker study of peanut allergy vaccine candidate
Study will take place at Imperial College London
Read More
Tag: Allergy Therapeutics
Setback for Allergy’s birch pollen immunotherapy
Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.
Read More
Allergy Therapeutics kicks off dosing in grass immunotherapy trial
Allergy Therapeutics has begun dosing in a mid-stage trial designed to assess the dose-response and safety of its ultra-short course PQ Grass immunotherapy, which targets the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.
Read More
Allergy Therapeutics eyes 15% sales jump
UK group Allergy Therapeutics has announced that its sales for the year are on track to overshoot market expectations at £64.1 million, as its hay fever vaccines continue to gain ground in core European markets.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
